Deborah R. Liptzin

Deborah R. Liptzin

Auto-generated profile, based on publicly available information

Deborah R. Liptzin

Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington School of Medicine , Seattle, WA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
CEChristopher M. Evans
Christopher M. Evans
DRDorota S. Raclawska
Dorota S. Raclawska
FTFani Ttofali
Fani Ttofali
DLDeborah R. Liptzin
Deborah R. Liptzin
AFAshley A. Fletcher
Ashley A. Fletcher
BDBurton F. Dickey
Burton F. Dickey
In asthma, airflow obstruction is thought to result primarily from inflammation-triggered airway smooth muscle (ASM) contraction. However, anti-inflammatory and smooth muscle-relaxing treatments are often temporary or ineffective. Overproduction of the mucin MUC5AC is an additional disease feature that, while strongly associated pathologically, is poorly understood functionally. Here we show that Muc5ac is a central effector of allergic inflammation that is required for airway hyperreactivity (AHR) to methacholine (MCh). In mice bred on two well-characterized strain backgrounds (C57BL/6 and BALB/c) and exposed to two separate allergic stimuli (ovalbumin and Aspergillus extract), genetic removal of Muc5ac abolishes AHR. Residual MCh responses are identical to unchallenged controls, and although inflammation remains intact, heterogeneous mucous occlusion decreases by 74%. Thus, whereas inflammatory effects on ASM alone are insufficient for AHR, Muc5ac-mediated plugging is an essential mechanism. Inhibiting MUC5AC may be effective for treating asthma and other lung diseases where it is also overproduced.

1 October 2015 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
LFLeland L. Fan
Leland L. Fan
MDMegan K. Dishop
Megan K. Dishop
CGCsaba Galambos
Csaba Galambos
FAFrederic B. Askin
Frederic B. Askin
FWFrances V. White
Frances V. White
RDRobin R. Deterding
Robin R. Deterding
Rationale: Children’s Interstitial and Diffuse Lung Disease (chILD) is a heterogeneous group of disorders that is challenging to categorize. In previous study, a classification scheme was successfully applied to children 0 to 2 years of age who underwent lung biopsies for chILD. This classification scheme has not been evaluated in children 2 to 18 years of age.Objectives: This multicenter interdisciplinary study sought to describe the spectrum of biopsy-proven chILD in North America and to apply a previously reported classification scheme in children 2 to 18 years of age. Mortality and risk factors for mortality were also assessed.Methods: Patients 2 to 18 years of age who underwent lung biopsies for diffuse lung disease from 12 North American institutions were included. Demographic and clinical data were collected and described. The lung biopsies were reviewed by pediatric lung pathologists with expertise in diffuse lung disease and were classified by the chILD classification scheme. Logistic regression ...

23 April 2015 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
DLDeborah R. Liptzin
Deborah R. Liptzin
LLLouis I. Landau
Louis I. Landau
LTLynn M. Taussig
Lynn M. Taussig

1 June 2020 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
DLDeborah R. Liptzin
Deborah R. Liptzin
KPKaci Pickett
Kaci Pickett
JBJohn T. Brinton
John T. Brinton
AAAmit Agarwal
Amit Agarwal
MFMartha P. Fishman
Martha P. Fishman
RDRobin R. Deterding
Robin R. Deterding
Rationale: Neuroendocrine cell hyperplasia of infancy (NEHI) is an important form of children’s interstitial and diffuse lung disease for which the diagnostic strategy has evolved. The prevalence of comorbidities in NEHI that may influence treatment has not been previously assessed. Objectives: To evaluate a previously unpublished NEHI clinical score for assistance in diagnosis of NEHI and to assess comorbidities in NEHI. Methods: We performed a retrospective chart review of 199 deidentified patients with NEHI from 11 centers. Data were collected in a centralized Research Electronic Data Capture registry and we performed descriptive statistics. Results: The majority of patients with NEHI were male (66%). The sensitivity of the NEHI Clinical Score was 87% (95% confidence interval [CI], 0.82–0.91) for all patients from included centers and 93% (95% CI, 0.86–0.97) for those with complete scores (e.g., no missing data). Findings were similar when we limited the population to the 75 patients diagnosed by lung biopsy (87%; 95% CI, 0.77–0.93). Of those patients evaluated for comorbidities, 51% had gastroesophageal reflux, 35% had aspiration or were at risk for aspiration, and 17% had evidence of immune system abnormalities. Conclusions: The NEHI Clinical Score is a sensitive tool for clinically evaluating NEHI; however, its specificity has not yet been addressed. Clinicians should consider evaluating patients with NEHI for comorbidities, including gastroesophageal reflux, aspiration, and immune system abnormalities, because these can contribute to the child’s clinical picture and may influence clinical course and treatment.

1 September 2016 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
DLDeborah R. Liptzin
Deborah R. Liptzin
MGMelanie C. Gleason
Melanie C. Gleason
LCLisa C. Cicutto
Lisa C. Cicutto
CCChris L. Cleveland
Chris L. Cleveland
DSDonna J. Shocks
Donna J. Shocks
SSStanley J. Szefler
Stanley J. Szefler

18 July 2018 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
DLDeborah R. Liptzin
Deborah R. Liptzin
CBChristopher D. Baker
Christopher D. Baker
JDJeffrey R. Darst
Jeffrey R. Darst
JWJason P. Weinman
Jason P. Weinman
MDMegan K. Dishop
Megan K. Dishop
RDRobin R. Deterding
Robin R. Deterding